{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Nutriband Inc."},"Symbol":{"label":"Symbol","value":"NTRB"},"Address":{"label":"Address","value":"121 SOUTH ORANGE AVENUE,SUITE 1500, ORLANDO, Florida, 32801, United States"},"Phone":{"label":"Phone","value":"+1 407 377-6695"},"Industry":{"label":"Industry","value":"Industrial Specialties"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products."},"CompanyUrl":{"label":"Company Url","value":"https://www.nutriband.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alan Smith","title":"COO & President-4P Therapeutics"},{"name":"Gareth R. Sheridan","title":"Chief Executive Officer & Director"},{"name":"Jeffrey Patrick","title":"Chief Scientific Officer"},{"name":"Larry M. Dillaha","title":"Chief Medical Officer"},{"name":"Patrick Ryan","title":"Chief Technical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}